Reuters reported:

The U.S. health regulator will review Pfizer (PFE.N) and German partner BioNTech SE’s (22UAy.DE) application for full approval of their COVID-19 vaccine in people 16 years and older by January, the companies said on Friday.

The vaccine is among the three being used in the United States under the Food and Drug Administration’s emergency use authorization alongside shots from Johnson & Johnson (JNJ.N)and Moderna Inc (MRNA.O).

Pfizer/BioNTech finished submitting their application for a full U.S. approval in May and the agency will review the data under its “priority review” pathway.

Similar Posts

Leave a Reply

Your email address will not be published.